Herpes Labialis News and Research

RSS

Herpes labialis or "orolabial herpes" is an infection of the lip by herpes simplex virus. An outbreak typically causes small blisters or sores on or around the mouth commonly known as cold sores or fever blisters.

US FDA approves Lipsovir for cold sores

The US Food and Drug Administration (FDA) has now approved Lipsovir, i.e. granted Medivir's New Drug Application (NDA) for the use of acyclovir and hydrocortisone for early treatment of recurrent cold sores to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented.

3 Aug 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

NanoBio successfully completes phase 2b study in Herpes labialis

NanoBio Corporation reported top-level findings from its phase 2b study of NB-001, a topical lotion to treat herpes labialis (cold sores).

18 Mar 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008

NanoBio expands drug development team

NanoBio Corporation has announced the addition of four new scientists to its drug development team.

26 Sep 2007

New topical lotion safely treats nail fungus without side effects

A new topical lotion that penetrates the skin deeply enough to target and eliminate serious skin infections, but without being systemically absorbed, has shown a high degree of safety and tolerability in patients with onychomycosis, or toenail fungus, a new study has shown.

25 Sep 2007

ViroPharma receives orphan drug designation for Maribavir

ViroPharma Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for maribavir for prevention of cytomegalovirus (CMV) viremia and disease in the populations at-risk.

7 Feb 2007

FDA grants fast track status for ViroPharma's Maribavir

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for maribavir, an oral antiviral drug candidate for the prevention of cytomegalovirus (CMV) infection in allogeneic bone marrow (stem cell) and solid organ transplant patients.

7 Feb 2006